High Growth Tech Stocks In Switzerland October 2024

The Swiss market recently experienced a modest decline, influenced by larger-than-expected U.S. consumer price inflation data and an increase in initial jobless claims, with the SMI index closing down by 45.17 points at 12,077.78. In this climate of fluctuating market sentiment, identifying high growth tech stocks in Switzerland requires careful consideration of their resilience to economic shifts and their potential for innovation-driven expansion amidst broader economic challenges.

Top 10 High Growth Tech Companies In Switzerland

Name	Revenue Growth	Earnings Growth	Growth Rating
LEM Holding	8.69%	18.43%	★★★★☆☆
Santhera Pharmaceuticals Holding	24.55%	35.40%	★★★★★★
ALSO Holding	12.58%	26.76%	★★★★☆☆
Comet Holding	19.66%	47.84%	★★★★★☆
Temenos	7.60%	14.36%	★★★★☆☆
SoftwareONE Holding	8.59%	52.33%	★★★★★☆
Addex Therapeutics	26.51%	33.31%	★★★★★☆
Basilea Pharmaceutica	9.24%	33.25%	★★★★★☆
MCH Group	4.41%	100.62%	★★★★☆☆
Sensirion Holding	13.86%	102.68%	★★★★☆☆

Click here to see the full list of 12 stocks from our SIX Swiss Exchange High Growth Tech and AI Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

ALSO Holding (SWX:ALSN)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: ALSO Holding AG is a technology services provider for the ICT industry, operating in Switzerland, Germany, the Netherlands, Poland, and internationally with a market cap of CHF3.22 billion.

Operations: With a market cap of CHF3.22 billion, ALSO Holding AG generates revenue primarily from its Central Europe and Northern/Eastern Europe segments, totaling €4.62 billion and €5.24 billion respectively.

ALSO Holding AG, amidst a challenging market, has demonstrated resilience with a forecasted revenue growth of 12.6% annually, outpacing the Swiss market's average of 4.3%. This growth is complemented by an impressive projected annual earnings increase of 26.8%, significantly above the national benchmark of 11.6%. Despite recent setbacks including a year-over-year earnings decline of 20.4%, the company's commitment to innovation and market expansion is evident from its R&D investments, which are crucial for sustaining long-term competitiveness in the high-tech industry. At a recent conference, ALSO underscored strategies to leverage emerging technologies, aiming to reverse current downturns and capitalize on anticipated sector recoveries.

• Get an in-depth perspective on ALSO Holding's performance by reading our health report here.

• Assess ALSO Holding's past performance with our detailed historical performance reports.

Basilea Pharmaceutica (SWX:BSLN)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company dedicated to developing products for oncology and anti-infectives, with a market capitalization of CHF547.27 million.

Operations: Basilea Pharmaceutica focuses on developing pharmaceutical products in oncology and anti-infectives, generating CHF149.02 million from these activities.

Basilea Pharmaceutica, navigating through a volatile market, anticipates a revenue growth of 9.2% annually, outperforming the Swiss market average of 4.3%. This growth trajectory is bolstered by recent expansions in drug indications and extended market exclusivity, which could secure sustained earnings. Notably, the company's R&D commitment is evidenced by its forecast to pivot to profitability within three years with an expected annual profit surge of 33.2%. Recent updates include raised financial guidance for 2024 with projected revenues hitting CHF 203 million and profits at CHF 60 million, reflecting strategic adaptability and potential in high-growth sectors.

• Click here and access our complete health analysis report to understand the dynamics of Basilea Pharmaceutica.

• Review our historical performance report to gain insights into Basilea Pharmaceutica's's past performance.

Temenos (SWX:TEMN)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Temenos AG develops, markets, and sells integrated banking software systems to financial institutions globally, with a market cap of CHF4.59 billion.

Operations: The company generates revenue primarily from its Product segment, contributing $879.99 million, and its Services segment, adding $132.98 million.

Temenos, a Swiss tech firm, is navigating the competitive landscape of financial software with strategic executive appointments and significant share buybacks. Recently, the company repurchased shares worth CHF 200 million, enhancing shareholder value. This move coincides with the appointment of Barb Morgan as Chief Product and Technology Officer, signaling a robust focus on AI-driven solutions for global financial institutions. With R&D expenses reflecting a commitment to innovation (7.6% of revenue), Temenos is poised for sustained growth, outpacing the Swiss market's average with projected revenue increases of 7.6% annually and earnings growth forecasted at 14.4% per year. These developments underscore Temenos' adaptive strategies in an evolving tech landscape.

• Click to explore a detailed breakdown of our findings in Temenos' health report.

• Evaluate Temenos' historical performance by accessing our past performance report.

Summing It All Up

• Unlock more gems! Our SIX Swiss Exchange High Growth Tech and AI Stocks screener has unearthed 9 more companies for you to explore.Click here to unveil our expertly curated list of 12 SIX Swiss Exchange High Growth Tech and AI Stocks.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com